Author ORCID Identifier
Immunosuppression with rituximab in immune-mediated thrombotic thrombocytopenic purpura helps decrease production of autoantibody mediating ADAMTS13 clearance from circulation. Failure to respond to rituximab in a satisfactory way or made difficult by adverse events to the medication does not represent a reason to stop considering anti-CD20 therapies to control antibody production. Therefore, both of atumumab and obinutuzumab with specificity to CD20, represent potentially valuable therapeutic tools in patients who are not candidates for rituximab. Commentary on: Doyle et al. The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura. Br J Haematol. 2022;198:391-396.1.
anti-CD20 therapeutic options, immune-mediated, thrombotic thrombocytopenic purpura
British Journal of Haematology
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Maitta RW. Anti-CD20 therapeutic options in immune-mediated thrombotic thrombocytopenic purpura. Br J Haematol. 2022;198:225–226. https://doi.org/10.1111/bjh.18215